Belgian-Italian Trial to Evaluate the Efficacy and Safety of Below The Knee (BTK) Treatment With the Luminor 14 Paclitaxel Coated Percutaneous Transluminal Angioplasty Balloon Catheter of iVascular

NCT ID: NCT03845543

Last Updated: 2024-11-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 150 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-11-28
• Study Completion Date: 2023-01-26

Brief Summary

The BIBLIOS trial investigates the efficacy and safety of BTK treatment of patients suffering from critical limb ischemia (Rutherford 5) with the Luminor-14 Paclitaxel coated Percutaneous Transluminal Angioplasty Balloon catheter of iVascular. An expected total of 150 patients will be treated. Infrapopliteal lesions will be treated during this trial. The Paclitaxel eluting balloon Luminor-14 is designed for percutaneous transluminal angioplasties in which the balloon will dilate the artery upon inflation. The balloon is coated with Paclitaxel intended to avoid cellular proliferation. The drug is released by means of rapid inflation as to release a high dose in a short amount of time. Patients will be invited for a follow-up visit at 1, 6 and 12 months post-procedure. The primary efficacy endpoint is defined as freedom from major adverse limb events, defined as above the ankle target limb amputations or major reintervention to the target lesions at 6 months. The primary safety endpoint is freedom from major adverse limb event at 30 days. The secondary endpoints consist of functional flow in target vessel, freedom from clinically driven target lesion revascularisation, above the ankle amputation free survival and limb salvage at 6 and 12 months, and also procedural success, wound healing status and wound healing time.

Detailed Description

The objective of this clinical investigation is to assess the safety and efficacy of the Luminor-14 DCB for the treatment of infrapopliteal lesions patients with critical limb ischemia.

The patients will be selected based on the investigator's assessment, evaluation of the underlying disease and the eligibility criteria. The patient's medical condition should be stable, with no underlying medical condition which would prevent them from performing the required testing or from completing the study. Patients should be geographically stable, willing and able to cooperate in this clinical study, and remain available for long term follow-up. The patient is considered enrolled in the study after obtaining the patients informed consent, if there is full compliance with the study eligibility criteria and after successful guidewire passage through the study target lesion.

Prior to the index procedure the following will be collected: an informed consent for data collection, demographics, medical history, medication record, physical examination, clinical category of acute limb ischemia (Rutherford category), the resting ankle-brachial index (ABI), life quality and if applicable a wound assessment.

During the procedure the guidewire will cross the entire study lesion after which the lesion will be assessed through angiography. A pre-dilatation with a standard non-drug-coated balloon will be performed followed by a dilatation of the lesion with a Luminor-14 balloon (iVascular). If dilatation was not successful (>30% stenosis, perforation, occlusive or flow limiting dissection) prolonged inflation should be attempted after which bail-out stenting with a non-drug-coated dedicated BTK stent is allowed in case of inadequate results.

The regular follow-up is necessary to monitor the condition of the patient and the results of the procedure. Patients will be invited on weekly follow-up, with special attention to wound healing status at each visit until the wound is completely healed. The other required follow-up visits are 1,6 and 12 months follow-ups. During these visit the following data will be collected: medication record, physical exam, wound assessment and healing status, quality of life, duplex ultrasound of target vessel and possible adverse events.

Conditions

Peripheral Arterial Disease

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Luminor-14 paclitaxel eluting balloon

Pre-dilatation of 180 seconds with a standard non-drug-coated semi-compliant balloon followed by a dilatation with a Luminor-14 paclitaxel eluting balloon (3µg/mm² balloon surface).

Group Type: EXPERIMENTAL

Luminor-14 Paclitaxel eluting balloon

Intervention Type: DEVICE

Patients will be treated with the Luminor-14 paclitaxel eluting balloon

Interventions

Luminor-14 Paclitaxel eluting balloon

Patients will be treated with the Luminor-14 paclitaxel eluting balloon

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Males or non-pregnant females ≥ 18 years of age at the time of consent. Females of childbearing potential have a negative pregnancy test <7 days before the procedure and are willing to use a reliable method of birth control for the duration of study participation. Female participants will be exempted from this requirement in case they are sterile, infertile or have been post-menopausal for at least 12 months
• Subject has been informed of and understands the nature of the study and provides signed informed consent to participate in the study. If the subject possesses the ability to understand and provide informed consent but due to physical inability, the subject cannot sign the informed consent form. An impartial witness may sign on behalf of the subject.
• Willing to comply with all required follow-up visits
• Rutherford Classification 5
• Significant degree of stenosis >70% or chronic total occlusion (CTO)
• Infrapopliteal lesion: P3 to the ankle-joint level (not below-the-ankle (BTA)); full length lesions or tandem lesions are allowed
• Wound, Ischemia, foot Infection (WIfI) tissue loss grade 1-2 at baseline
• WIfI foot infection grade of 0-2 at baseline
• WIfI ischemia grade 2-3 at baseline
• Estimated life expectancy ≥ 1 year
• Multiple lesions can be treated if they are located in separate vessels per standard of care but only one (1) BTK vessel can be considered as the target lesion/vessel and need to be treated according the Clinical Investigation Protocol (CIP) guidelines.
• Target vessel should give direct or indirect run-off to the foot (clearly documented in a foot/BTA angiogram)
• Patients with in-flow lesions can be included if the lesions are treated successfully (residual stenosis ≤30%) with the same drug coated balloon (DCB) platform, bail-out stenting with a bare-metal stent (BMS).
• Successful pre-dilatation of the target lesion (≤30% residual stenosis)

Exclusion Criteria

• Previous bypass graft in the target limb
• Acute limb ischemia, defined as symptom onset during less than 14 days prior to the index procedure
• Prior or planned above-the-ankle amputation to the target limb (this does not apply to ray amputation of ≤2 digits, simple digital amputations or ulcer debridement)
• Previous DCB treatment in target vessel 6 months prior to index procedure
• WIfI tissue loss grade 0 or 3 at baseline
• WIfI foot infection grade 3 at baseline
• WIfI ischemia grade 0-1 at baseline
• Any systemic infection or immunocompromised state. Patients with an ascending infection/deep foot infection or abscess/white blood count (WBC)≥12.000/or febrile state or C reactive protein (CRP)>5mg/L
• Endovascular or surgical procedure (not including diagnostic procedures, planned simple digital amputation or wound debridement) to the target limb within 30 days after the index procedure
• Existing stent implant in the target vessel
• Use of alternative therapies: atherectomy, cutting/scoring balloons, laser, …
• Known coagulopathy, hypercoagulable state, bleeding diathesis, other blood disorder, or a platelet count less than 80.000/μL or greater than 500.000/μL
• Any subject in which antiplatelet, anticoagulant or thrombolytic therapy is contraindicated
• Myocardial infarction, coronary thrombolysis or angina less than 30 days prior to the index procedure
• History of stroke or transient ischemic attack (TIA) less than 90 days prior to the index procedure
• Known hypersensitivity or contraindication to nickel-titanium alloy (Nitinol)
• Has other comorbidities that, in the opinion of the investigator, would preclude them from receiving this treatment and/or participating in study-required follow-up
• Patients on haemodialysis
• Known hypersensitivity or allergy to contrast agents that cannot be medically managed
• Known hypersensitivity or allergy to heparin, aspirin, paclitaxel, clopidogrel or other antiplatelet/anticoagulant therapies
• Inadequate inflow lesion treatment (>30% residual stenosis)
• Inadequate result of pre-dilatation (>30% residual stenosis)
• Inadequate run-off to the foot
• Bilateral BTK enrolment in this study

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

ID3 Medical

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Koen Deloose, MD

Role: STUDY_DIRECTOR

ID3 Medical

Locations

OLV Ziekenhuis Aalst

Aalst, Oost-Vlaanderen, Belgium

Imelda Hospital

Bonheiden, , Belgium

A.Z. Sint-Blasius

Dendermonde, , Belgium

Z.O.L.

Genk, , Belgium

AZ Groeninge

Kortrijk, , Belgium

Regionaal Ziekenhuis Heilig Hart

Tienen, , Belgium

Policlinico Abano Terme

Abano Terme, Padua, Italy

IRCCS Policlinico San Donato

San Donato, , Italy

Hospital Univ. Germans Trias I Pujol

Badalona, , Spain

Countries

Belgium; Italy; Spain

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

BIBLIOS-Luminor14BTK

Identifier Type: -

Identifier Source: org_study_id